Novavax has announced that Gregory Glenn, President of Research & Development, will present on NVX-CoV2373, the company’s COVID-19 vaccine, at The New York Academy of Science (NYAS) event, ‘The Quest for a COVID-19 Vaccine.’
Webinar details are as follows:
Presentation title: Efficacy Data Updates from Novavax’ Protein-based Vaccine Candidate
Date: February 2, 2021
Time: 4:00 pm ET
Presenter: Dr. Glenn
Novavax announced interim data last week on its protein-based COVID-19 vaccine candidate that demonstrated efficacy of 89.3% in a pivotal Phase III clinical trial taking place in the United Kingdom (UK). The data from this UK Phase III trial and a South Africa Phase IIb study were the first to demonstrate clinical efficacy against newer circulating UK and South Africa COVID-19 variants.
To register for the webinar please visit the NYAS website.
NVX-CoV2373 is a protein-based vaccine candidate engineered from the genetic sequence of SARS-CoV-2, the virus that causes COVID-19 disease. NVX-CoV2373 was created using Novavax’ recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein and is adjuvanted with Novavax’ patented saponin-based Matrix-M to enhance the immune response and stimulate high levels of neutralizing antibodies. NVX-CoV2373 contains purified protein antigen and can neither replicate, nor can it cause COVID-19. In preclinical studies, NVX-CoV2373 induced antibodies that block binding of spike protein to cellular receptors and provided protection from infection and disease. It was generally well-tolerated and elicited robust antibody response numerically superior to that seen in human convalescent sera in Phase I/II clinical testing. NVX-CoV2373 is currently being evaluated in two pivotal Phase III trials: a trial in the UK that completed enrolment in November and the PREVENT-19 trial in the US. and Mexico that began in December. It is also being tested in two ongoing Phase II studies that began in August: A Phase IIb trial in South Africa, and a Phase I/II continuation in the US and Australia.
